Premium
p53 immunoreactivity in non‐melanoma skin cancer from immunosuppressed and immunocompetent individuals: a comparative study of 246 tumours
Author(s) -
Khorshid S.M.,
Glover M.T.,
Churchill L,
McGregor J.M.,
Proby C.M.
Publication year - 1996
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.1600-0560.1996.tb01471.x
Subject(s) - pathology , melanoma , basal cell carcinoma , medicine , skin cancer , seborrheic keratosis , staining , basal (medicine) , immunohistochemistry , basal cell , cancer , cancer research , insulin
p53 immunoreactivity was examined in 132 cutaneous non‐melanoma tumours from renal transplant recipients and in 114 histologically matched specimens from immunocompetent individuals. Skin lesions examined included 52 viral warts, 50 clysplastic keratoses, 51 intraepidermal carcinomas (IEC), 50 invasive squamous cell carcinomas (SCC) and 43 basal cell carcinomas (BCC). Overall, 51% (51/101) pre‐malignant skin lesions and 45% (42/93) non‐melanoma skin cancers (NMSC) showed p53 immunoreactivity, with extensive (> 50% cells positive) p53 staining in 27% (27/101) of pre‐malignant and 20% (19/93) of malignant lesions. 17% (9/52) viral warts showed p53 immunoreactivity, but this was limited to focal or basal p53 staining. p53 immunoreactivity in all tumours was less in transplant than in non‐transplant patients and this reached statistical significance for SCCs (p = 0.03).